Form 4: Lyell Immunopharma Director Richard Klausner Reports Stock Option Grant and Beneficial Ownership

Director Richard Klausner reports the acquisition of stock options and updates to beneficial ownership of Lyell Immunopharma shares.

Summary

• Richard Klausner, a director of Lyell Immunopharma, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The report indicates that Klausner was granted options to purchase 130,000 shares of common stock on June 14, 2024, at an exercise price of $2.36 per share.
• These options vest on the earlier of the next annual meeting of stockholders following June 14, 2024, or the first anniversary of that date, contingent upon continuous service.
• Klausner directly owns 2,967,834 shares of common stock.
• He also indirectly owns 685,365 shares through trusts (The Ariella Klausner Delaware Trust, The Eli Klausner Delaware Trust and The Olivia Klausner Delaware Trust) for which he is a grantor.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, indicating routine transactions. Sentiment is neutral.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders.

Future Outlook

The vesting of the options is contingent upon continued service, suggesting an expectation of Klausner's ongoing involvement with the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders are informed about changes in beneficial ownership by a company director.

Key Dates